On this page
At a glance / Pepti
Our take
Pepti’s MOTS-c offer is specific enough to inspect for format and cost, while its metabolic framing remains a separate evidence question. The vial price ladder does not tell you whether care is appropriate or whether a hoped-for outcome is established. Keep the offered package, refill calendar and clinical explanation together before giving the service a place on your shortlist.
- Published offer
- MOTS-c injectable; prescription decision required
- Advertised starting price
- $259 / 10 mg; options through $349 / 50 mg
- Billing basis
- Automatic refill subscription; approximately 28-day supply, not a calendar month
- Independent license verification
- Not completed in this review
- Optional at-home lab
- +$149 for the separately offered kit; confirm the selected service.
- Refund boundary
- Denial/pre-pharmacy cancellation refunds described; no returns after shipment. Confirm order status.
Useful details
- Format and package-price choices are visible
- Public policy describes the refill commitment
What to weigh
- Pen was shown sold out
- Biological marketing does not resolve clinical benefit
A review of published information, not a treatment experience or a clinical quality rating. Source check: 2026-10-28.
Two questions, not one
There are two decisions to separate when reading a MOTS-c offer: what the evidence can support, and what a provider is actually proposing to sell. Pepti gives you a visible service listing to examine. It does not resolve whether treatment makes sense for your circumstances. Research interest, a biological explanation and an appropriate clinical choice are different things. Use the listing to prepare questions for a qualified professional rather than letting the ease of shopping answer a medical question.
What the selector shows
The checked page lists injectable vials at $259 for 10 mg, rising to $349 for 50 mg through intermediate options. The pen is marked sold out. Those details describe the offer at the time of review; they do not establish that every option will be prescribed or available to an individual reader. Compare the actual format being offered. An attractive device image should not set expectations for the preparation, handling or support that a vial prescription would involve.
Put claims in the right category
A consumer does not need to become a laboratory researcher to ask whether a statement concerns a mechanism, an animal finding, a human study or marketing. Ask which category supports the particular claim being made. Then ask whether the studied preparation and use match the proposed product. A provider-service review cannot turn those answers into an assurance of metabolic benefit. We do not use a service score to imply that the evidence for a molecule is stronger than it is.
The commitment is a calendar question
The billing policy describes automatic supply-based renewals, commonly every 28 days. Write the recurrence next to the quoted amount. If you budget using calendar months, a refill schedule can shift across the dates you normally expect to pay bills. Ask how a plan change affects future charges and how to stop another refill before it enters processing. Decide what questions need answers before enrollment, rather than assuming a cancellation option makes the first transaction a risk-free trial. The administered-product evidence guide examines why the human exercise findings cannot simply be transferred to this service.
What remains to be checked
This review covers published information, without completing medical intake or independently verifying the relevant prescriber and pharmacy licenses. Ask for the parties responsible for your proposed care, the exact product information and the eligibility decision for your state. Also ask which additional services could be proposed and which are optional. If an evidence or quality document is supplied, check what it covers rather than reading its existence as a blanket assurance. The same care applies to any claim about oversight or testing.
Our take on the offering
Pepti is a candidate for a practical conversation about product format, recurring cost and access to clinical answers. The visible price ladder is helpful for documenting the offer, while the research questions and patient-specific eligibility stay unresolved by the storefront. A good next step is a written list of questions, including the planned total and the grounds for recommending the proposed care. We have no firsthand fulfillment or treatment experience to report, and this review makes no promise about energy, weight or longevity.
Common questions
What was the starting MOTS-c package?
The checked vial selector started at 10 mg for $259, with larger listed options through 50 mg for $349. The pen was marked sold out.
Does the quoted amount repeat every calendar month?
The subscription terms use the supply cycle, commonly 28 days. Ask for the actual next-charge date and whether the proposed plan changes the amount or timing.
Does this review confirm the clinician and pharmacy licenses?
No. This is a review of published information. It does not independently verify the professional or dispensing permissions applicable to your particular address and proposed prescription.
Sources & further reading
Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.
- Pepti MOTS-c published offering
- Pepti billing and subscription terms
- Pepti cancellation policy
- Pepti refund policy
Source review: 2026-10-28. Provider terms and policy documents can change.